Developer docs
API playgroundTry for free, no card

Search company profiles

Adocia

Full company profile

uuid0005bo9

Namestring
Adocia
Legal namestring
ADOCIA
Websiteurl
adocia.com
Company typeenum
Public
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes therapeutics, insulin formulations, biopharmaceutical licensing, peptide protein delivery, cell therapy scaffolds
Industry2 codes
PRIMARYHLAAAHAD
Insulin & Analog Biosimilars
SECONDARYHLAIAFAB
Insulin & Analog Biosimilars
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Diabetes & Obesity Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Adocia generates revenue through licensing agreements with pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical and regulatory achievements, and double-digit royalties on net sales. A $20 million milestone payment is tied to marketing authorization in China for BioChaperone Lispro.

pharmiweb.com
2Fundraising
TypeOne Time License
Description

Adocia raises capital through private placements and public offerings to fund R&D operations. The company completed a €10 million fundraising in December 2025 and a €9.7 million private placement in February 2025.

pharmiweb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BioChaperone®
Description

Proprietary technology platform for innovative insulin formulations

adocia.com
+1 more record
Core offering1 text field

Adocia develops innovative formulations of already-approved therapeutic peptides and proteins, principally insulins and metabolic hormones, for the treatment of type 1 and type 2 diabetes and obesity. The company leverages its proprietary BioChaperone formulation platform and AdoShell immunoprotective scaffold technology, out-licensing clinical-stage drug candidates to pharmaceutical partners after proof-of-concept in humans in exchange for upfront payments, milestone payments, and royalties on net sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials
+3 more records
Product overview1 text field

Adocia is a clinical-stage biotechnology company offering a portfolio of innovative diabetes and obesity treatments built on its proprietary BioChaperone technology platform. The product portfolio includes: BioChaperone Lispro (THDB0206), an ultra-rapid insulin formulation; BioChaperone Combo, a co-formulation of lispro and glargine; ADO09, a co-formulation of pramlintide and insulin A21G; and AdoShell Islets, an immunoprotective cell therapy scaffold. These products range from innovative formulations of already-approved peptides and proteins to specialized delivery technologies.

Product and service2 records
1BioChaperone Lispro (THDB0206)
CategoryDiabetes therapeutics (ultra-rapid insulin)
Description

Ultra-rapid insulin formulation combining Adocia's proprietary BioChaperone technology with insulin lispro. Demonstrated non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials for both type 1 and type 2 diabetes patients, and out-licensed to Tonghua Dongbao for China and Asian markets.

2BioChaperone Combo
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Tonghua Dongbao
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-01-01
Description

Licensing agreement signed in 2018 for BioChaperone Lispro (THDB0206) in China and Asian markets. Includes $20 million milestone payment upon marketing authorization in China plus double-digit royalties on net sales. Partner completed Phase 3 trials with positive results in both type 1 and type 2 diabetes patients.

investing.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Major historical partnership representing over $150 million in revenue. The partnership involved insulin formulation technologies developed by Adocia.

Strategic tierMinorTypeOthers
Description

Web hosting provider for Adocia's corporate website.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage and commercial biotech focused on endocrine diseases, including inhaled insulin (Afrezza) and GLP-1/glucagon programs. Highly comparable to Adocia in developing reformulated/innovative insulin and metabolic hormone therapeutics.

TypeDirect peer
Description

Danish peptide therapeutics company developing novel GLP-1, amylin, and other metabolic peptides for diabetes and obesity. Direct peer given shared focus on innovative peptide/protein formulations for metabolic diseases.

TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapeutics for type 1 diabetes (T1D) and other metabolic diseases. Comparable in being a small-cap clinical-stage company tackling diabetes with innovative mechanisms.

4Biolaxy (Tonghua Dongbao-related biosimilars)
TypeEmerging player
Description

Tonghua Dongbao is one of China's largest insulin manufacturers and Adocia's licensing partner for BioChaperone Lispro. A key regional peer given its commercial insulin franchise in China and direct involvement in the THDB0206 program.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with a major insulin franchise (Lantus, Apidra, Toujeo) and broad metabolic disease portfolio. Represents the type of large pharma partner or competitor Adocia engages with for licensing and competes against commercially.

TypeBroad incumbent
Description

World's largest insulin producer (NovoLog, Fiasp, Levemir, Tresiba) and dominant GLP-1 player (Ozempic, Wegovy). Adocia's CFO/COO came from Novo Nordisk, and Novo represents both a benchmark competitor and a potential strategic acquirer/partner.

TypeBroad incumbent
Description

Maker of Humalog and Lyumjev (the comparator in Adocia's Phase 3 trials) and major diabetes/obesity player. Historical Adocia partner (>$150M in past revenue) and a key reference point for any future Western-market licensing deal.

TypeEmerging player
Description

Has a leading cell-therapy program (VX-880/zimislecel) for type 1 diabetes. Highly comparable to Adocia's AdoShell Islets program as a competitor/peer in pursuit of a functional cell-based cure for T1D.

9Sigilon Therapeutics
TypeEmerging player
Description

Developer of cell-encapsulation therapies for type 1 diabetes and other diseases. Directly comparable to Adocia's AdoShell immunoprotective scaffold approach to enable cell therapy without chronic immunosuppression.

TypeEmerging player
Description

Now a Sanofi subsidiary focused on autoimmune and inflammatory diseases including type 1 diabetes (Tzield). Comparable emerging diabetes biotech that achieved a strategic exit via acquisition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adocia

Diabetes & Obesity Biopharmaceuticalsadocia.com

Adocia firmographics

Firmographics
Name
Adocia
Legal name
ADOCIA
Website
https://adocia.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Adocia industry classification

Industry
Product category
Diabetes & Obesity Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAHAD
Insulin & Analog Biosimilars
SECONDARYHLAIAFAB
Insulin & Analog Biosimilars

Keywords

  • Diabetes therapeutics
  • Insulin formulations
  • Biopharmaceutical licensing
  • Peptide protein delivery
  • Cell therapy scaffolds

Where Adocia is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Adocia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Adocia generates revenue through licensing agreements with pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical and regulatory achievements, and double-digit royalties on net sales. A $20 million milestone payment is tied to marketing authorization in China for BioChaperone Lispro.
  2. Fundraising: Adocia raises capital through private placements and public offerings to fund R&D operations. The company completed a €10 million fundraising in December 2025 and a €9.7 million private placement in February 2025.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Adocia product offering

Product offering

Core offering

Adocia develops innovative formulations of already-approved therapeutic peptides and proteins, principally insulins and metabolic hormones, for the treatment of type 1 and type 2 diabetes and obesity. The company leverages its proprietary BioChaperone formulation platform and AdoShell immunoprotective scaffold technology, out-licensing clinical-stage drug candidates to pharmaceutical partners after proof-of-concept in humans in exchange for upfront payments, milestone payments, and royalties on net sales.

Product overview

Adocia is a clinical-stage biotechnology company offering a portfolio of innovative diabetes and obesity treatments built on its proprietary BioChaperone technology platform. The product portfolio includes: BioChaperone Lispro (THDB0206), an ultra-rapid insulin formulation; BioChaperone Combo, a co-formulation of lispro and glargine; ADO09, a co-formulation of pramlintide and insulin A21G; and AdoShell Islets, an immunoprotective cell therapy scaffold. These products range from innovative formulations of already-approved peptides and proteins to specialized delivery technologies.

Differentiator

Problem solved

Functional benefit

Brands

  • BioChaperone®: Proprietary technology platform for innovative insulin formulations
  • AdoShell®

Products and services

  • BioChaperone Lispro (THDB0206) Ultra-rapid insulin formulation combining Adocia's proprietary BioChaperone technology with insulin lispro. Demonstrated non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials for both type 1 and type 2 diabetes patients, and out-licensed to Tonghua Dongbao for China and Asian markets.
  • BioChaperone Combo

Quantifiable outcome

  • Non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials
  • +3 more outcomes

Companies that use Adocia

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Adocia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Adocia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Tonghua DongbaocoreOEM/ Whitelabel/ Licensing Partner · 1 January 2018Licensing agreement signed in 2018 for BioChaperone Lispro (THDB0206) in China and Asian markets. Includes $20 million milestone payment upon marketing authorization in China plus double-digit royalties on net sales. Partner completed Phase 3 trials with positive results in both type 1 and type 2 diabetes patients.
  • Eli LillycoreOEM/ Whitelabel/ Licensing PartnerMajor historical partnership representing over $150 million in revenue. The partnership involved insulin formulation technologies developed by Adocia.
  • OVHminorOthersWeb hosting provider for Adocia's corporate website.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Adocia competitors and assessment

Company assessment

Direct peers

  • MannKind Corporation: Clinical-stage and commercial biotech focused on endocrine diseases, including inhaled insulin (Afrezza) and GLP-1/glucagon programs. Highly comparable to Adocia in developing reformulated/innovative insulin and metabolic hormone therapeutics.
  • Zealand Pharma: Danish peptide therapeutics company developing novel GLP-1, amylin, and other metabolic peptides for diabetes and obesity. Direct peer given shared focus on innovative peptide/protein formulations for metabolic diseases.
  • vTv Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for type 1 diabetes (T1D) and other metabolic diseases. Comparable in being a small-cap clinical-stage company tackling diabetes with innovative mechanisms.

Emerging players

  • Biolaxy (Tonghua Dongbao-related biosimilars): Tonghua Dongbao is one of China's largest insulin manufacturers and Adocia's licensing partner for BioChaperone Lispro. A key regional peer given its commercial insulin franchise in China and direct involvement in the THDB0206 program.
  • Vertex Pharmaceuticals: Has a leading cell-therapy program (VX-880/zimislecel) for type 1 diabetes. Highly comparable to Adocia's AdoShell Islets program as a competitor/peer in pursuit of a functional cell-based cure for T1D.
  • Sigilon Therapeutics: Developer of cell-encapsulation therapies for type 1 diabetes and other diseases. Directly comparable to Adocia's AdoShell immunoprotective scaffold approach to enable cell therapy without chronic immunosuppression.
  • Provention Bio (sanofi): Now a Sanofi subsidiary focused on autoimmune and inflammatory diseases including type 1 diabetes (Tzield). Comparable emerging diabetes biotech that achieved a strategic exit via acquisition.

Broad incumbents

  • Sanofi (Diabetes/General Medicines): Global pharmaceutical incumbent with a major insulin franchise (Lantus, Apidra, Toujeo) and broad metabolic disease portfolio. Represents the type of large pharma partner or competitor Adocia engages with for licensing and competes against commercially.
  • Novo Nordisk: World's largest insulin producer (NovoLog, Fiasp, Levemir, Tresiba) and dominant GLP-1 player (Ozempic, Wegovy). Adocia's CFO/COO came from Novo Nordisk, and Novo represents both a benchmark competitor and a potential strategic acquirer/partner.
  • Eli Lilly: Maker of Humalog and Lyumjev (the comparator in Adocia's Phase 3 trials) and major diabetes/obesity player. Historical Adocia partner (>$150M in past revenue) and a key reference point for any future Western-market licensing deal.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Adocia social profiles

Digital presence

Adocia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adocia leadership team

Management profile

Number of profiles

Profiles9 records

Adocia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adocia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adocia

What does Adocia do?

Adocia develops innovative formulations of already-approved therapeutic peptides and proteins, principally insulins and metabolic hormones, for the treatment of type 1 and type 2 diabetes and obesity. The company leverages its proprietary BioChaperone formulation platform and AdoShell immunoprotective scaffold technology, out-licensing clinical-stage drug candidates to pharmaceutical partners after proof-of-concept in humans in exchange for upfront payments, milestone payments, and royalties on net sales.

Is Adocia a public or private company?

Adocia is a public company. It is classified as public and is currently operating.

When was Adocia founded?

Adocia was founded in 2005. It employs 51 to 100 people.

Where is Adocia based?

Adocia is headquartered in Lyon, France, in the Europe region.

How does Adocia make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are fundraising.

Who are Adocia's main competitors?

Direct peers on record are MannKind Corporation, Zealand Pharma and vTv Therapeutics. Emerging players are Biolaxy (Tonghua Dongbao-related biosimilars), Vertex Pharmaceuticals, Sigilon Therapeutics and Provention Bio (sanofi). Broad incumbents are Sanofi (Diabetes/General Medicines), Novo Nordisk and Eli Lilly.

Does Adocia have an API?

No public API is recorded for Adocia.

What industry is Adocia in?

Adocia's product category is Diabetes & Obesity Biopharmaceuticals. Its primary akta.pro industry code is HLAAAHAD, Insulin & Analog Biosimilars, with a secondary code of HLAIAFAB, Insulin & Analog Biosimilars. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogADOCIA Presents Preclinical Data at ObesityWeek® 2026 Confirming the Potential of AdoXLong™ for Monthly Injections of PeptidesAdocia presented preclinical data on its AdoXLong platform at ObesityWeek 2026, showing extended circulation times for semaglutide and retatrutide. In pigs, the platform achieved half-lives of 153-159 hours, enabling once-monthly dosing, with body weight reduction comparable to semaglutide. The company plans to continue development toward clinical evaluation.Investing.comAdocia to present monthly incretin platform data at ObesityWeekAdocia will present preclinical data on its AdoXLong platform at ObesityWeek 2026 in Washington from November 14-17, 2026. The platform extends once-weekly incretin treatments to monthly administration via a biocompatible polymer, with a patent application filed in November 2025. The company plans to continue development toward clinical trials.YahooADOCIA to Present Preclinical Data from its AdoXLong™ Platform at ObesityWeek® 2026Adocia will present preclinical data on its AdoXLong platform at ObesityWeek 2026 in Washington, USA, on November 14. The platform enables once-monthly administration of incretin peptides, aiming to reduce discontinuation rates. The company plans to continue developing the platform toward clinical development.Business Wire BlogADOCIA Reports Third Quarter 2026 Financial Results and Provides a Business UpdateAdocia reported Q3 2026 financial results, with cash position of €8.4 million as of September 30, 2026, and a €7 million financing completed in October 2026. The financing, combined with cost reductions, extends cash runway to Q1 2028, and the company expects to reach a $20 million milestone payment for BC Lispro in China if marketing authorization is obtained.YahooADOCIA Announces a €7 Million Financing and the Extension of Its Cash Runway to 2028Adocia announced a €7 million financing on October 20, 2026, including a €3 million capital increase and a €4 million shareholder loan amendment. The cash runway is extended to Q1 2028, and to 2029 if the $20 million milestone payment for BC Lispro's Chinese marketing authorization is reached.The future of tradingAdocia names Stéphane Boissel as board chairman after Gérard Soula exits boardAdocia reshaped its board in 2026, naming Stéphane Boissel as chairman after co-founder Gérard Soula left. Jacky Vonderscher joined as independent director, Maureen Deehan was co-opted, and Suman Shirodkar was appointed as board observer.The future of tradingAdocia H1 Operating Income EUR -7.947 MillionAdocia reported a first-half operating loss of EUR 7.947 million and a net loss of EUR 8.641 million. Adjusted operating expenses for the period were EUR 9.024 million.Markets DailyAdocia (ADOCY) to Announce Earnings on ThursdayAdocia is expected to report earnings on September 24th, with analysts projecting a loss of $0.6609 per share. The company's stock opened at $11.80, and its financial ratios include a current ratio of 1.19 and a debt-to-equity ratio of 4.18.AInvestAdocia's Data Presented at EASD Annual Meeting, Breakthrough T1D CongressAdocia will present data on AdoShell platform scalability and BioChaperone Lispro's Phase 3 results at EASD and Breakthrough T1D Congress. The presentations cover full clinical outcomes for Chinese type 2 diabetes patients and pancreatic islet encapsulation advancements. The meetings are held in Milan and Philadelphia.AInvestThe Board Changes Adocia Didn't Need — Until the Runway Shrank to Two QuartersAdocia announced board changes on September 1, adding independent directors and a board observer after founder Gérard Soula stepped down. The company burned €10.1 million in H1 2026, leaving €9.7 million in cash, with a shareholder loan providing runway to early Q2 2027. The new board aims to secure partnerships to avoid further dilution.